United States Biotechnology & Medical Research

Genelux Corp (GNLX)

Track

Track

Over the past 90 days, Genelux Corp insiders have executed 12 transactions, all of which were sales totaling approximately $156,039. Key executives, including the CEO and Chief Scientific Officer, participated in these divestments. This activity coincides with a 19.3% decline in the stock price over the same period, with shares currently trading near their 52-week low.
Ticker: GNLX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Genelux Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.2
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
171.38
Quantity 21,986 -32.1%
Value US$2,355,077
3.8
Yu Yong Chief Scientific Officer Officer
Transaction date
Sale
Price
177.61
Quantity 48,236 -28.4%
Value US$2,180,848
3.4
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
400.57
Quantity 10,374 -34.0%
Value US$1,771,114
2.8
Smither John W Non-Executive Director
Transaction date
Sale
Price
2.91
Quantity 12,000 -11.6%
Value US$34,898
2.8
JOHN SMITHER Director Non-Executive Director
Transaction date
Proposed sale
Price
2.91
Quantity 12,000
Value US$34,898
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.93
Quantity 192 -0.3%
Value US$563
3.1
Thomas John Non-Executive Director
Transaction date
Planned sale
Price
2.98
Quantity 10,000 -2.1%
Value US$29,801
3.1
JOHNNY THOMAS Officer Officer
Transaction date
Proposed sale
Price
3.05
Quantity 10,000
Value US$30,500
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.98
Quantity 270 -0.4%
Value US$804
3.2
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
2.94
Quantity 2,798 -0.5%
Value US$8,226
3.4
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
2.97
Quantity 605 -0.4%
Value US$1,799
3.8
Yu Yong Chief Scientific Officer Officer
Transaction date
Sale
Price
2.97
Quantity 605 -0.4%
Value US$1,798
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.51
Quantity 240 -0.4%
Value US$602
3.8
Yu Yong SVP, Clinical Development Officer
Transaction date
Sale
Price
2.42
Quantity 906 -0.6%
Value US$2,193
3.4
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
2.42
Quantity 906 -0.6%
Value US$2,193
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.42
Quantity 345 -0.5%
Value US$835
3.2
Zindrick Thomas President and CEO Officer
Transaction date
Sale
Price
2.42
Quantity 3,582 -0.7%
Value US$8,668
3.1
Thomas John Non-Executive Director
Transaction date
Planned sale
Price
2.90
Quantity 10,000 -2.0%
Value US$28,957
3.1
JOHNNY THOMAS Officer Officer
Transaction date
Proposed sale
Price
2.98
Quantity 10,000
Value US$29,800
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
4.69
Quantity 165 -0.2%
Value US$774
3.1
Thomas John Non-Executive Director
Transaction date
Planned sale
Price
5.00
Quantity 10,000 -2.0%
Value US$50,008
3.1
JOHNNY THOMAS Director Non-Executive Director
Transaction date
Proposed sale
Price
5.56
Quantity 10,000
Value US$55,600
3.8
Yu Yong SVP, Clinical Development Officer
Transaction date
Sale
Price
5.37
Quantity 973 -0.7%
Value US$5,224
3.2
Zindrick Thomas President and CEO Officer
Transaction date
Planned sale
Price
5.37
Quantity 4,509 -0.8%
Value US$24,211
3.4
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
5.37
Quantity 973 -0.6%
Value US$5,224
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
5.37
Quantity 343 -0.5%
Value US$1,842
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
3.36
Quantity 580 -0.8%
Value US$1,948
3.8
Yu Yong SVP, Clinical Development Officer
Transaction date
Sale
Price
3.36
Quantity 3,219 -2.1%
Value US$10,807
3.2
Zindrick Thomas President and CEO Officer
Transaction date
Planned sale
Price
3.33
Quantity 12,673 -2.3%
Value US$42,159
3.4
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
3.36
Quantity 1,463 -0.9%
Value US$4,912
3.4
Cappello Joseph Chief Technical Officer Officer
Transaction date
Sale
Price
3.33
Quantity 1,270 -0.8%
Value US$4,225
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
3.36
Quantity 1,244 -1.8%
Value US$4,177
3.2
Zindrick Thomas President and CEO Executive Director
Transaction date
Sale
Price
2.92
Quantity 10,764 -5.3%
Value US$31,431
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Sale
Price
2.92
Quantity 1,259 -3.5%
Value US$3,676
2.6
Ryder Sean General Counsel Officer
Transaction date
Sale
Price
2.92
Quantity 4,475 -8.6%
Value US$13,067
3.4
Cappello Joseph VP, Pharmaceutical Development Officer
Transaction date
Sale
Price
2.92
Quantity 4,737 -8.3%
Value US$13,832
3.8
Yu Yong VP, Clinical Trial Operations Officer
Transaction date
Sale
Price
2.92
Quantity 5,579 -10.5%
Value US$16,291
3.3
JAMES L TYREE Director Non-Executive Director
Transaction date
Proposed sale
Price
2.46
Quantity 3,460
Value US$8,512
3.3
Tyree James L Non-Executive Director
Transaction date
Sale
Price
2.46
Quantity 3,460 -7.0%
Value US$8,512
Zak Lourie S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
2.34
Quantity 2,103 -4.9%
Value US$4,921
3.3
Smalling Ralph Head of Regulatory Officer
Transaction date
Planned sale
Price
2.34
Quantity 2,510 -13.3%
Value US$5,873
3.4
Cappello Joseph VP, Pharmaceutical Development Officer
Transaction date
Sale
Price
2.34
Quantity 6,300 -30.1%
Value US$14,742
3.2
Zindrick Thomas President and CEO Executive Director
Transaction date
Planned sale
Price
2.34
Quantity 14,315 -27.7%
Value US$33,497
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.57
Quantity 33,080 -5.2%
Value US$84,946
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.73
Quantity 31,777 -4.8%
Value US$86,732
3.3
Tyree James L Non-Executive Director
Transaction date
Planned sale
Price
2.60
Quantity 1,730 -3.5%
Value US$4,499
3.3
JAMES L TYREE Director Non-Executive Director
Transaction date
Proposed sale
Price
2.51
Quantity 1,730
Value US$4,342
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.62
Quantity 31,376 -4.5%
Value US$82,227
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.51
Quantity 20,384 -2.8%
Value US$51,182
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.70
Quantity 23,383 -3.2%
Value US$63,200
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.09
Quantity 42,818 -5.5%
Value US$89,614
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.17
Quantity 142,589 -15.4%
Value US$309,846
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
1.98
Quantity 107,045 -10.4%
Value US$211,960
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.05
Quantity 15,918 -1.5%
Value US$32,605
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.11
Quantity 51,630 -4.7%
Value US$108,862
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
2.29
Quantity 40,000 -3.5%
Value US$91,416
SZALAY 2010 RETAINED ANNUITY TRUST 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
2.18
Quantity 400,000
Value US$872,000
3.8
Yu Yong VP, Clinical Trial Operations Officer
Transaction date
Sale
Price
2.12
Quantity 6,849 -38.7%
Value US$14,520
2.4
Jewett Caroline Head of Quality Officer
Transaction date
Sale
Price
2.12
Quantity 4,961 -23.5%
Value US$10,517
2.6
Ryder Sean General Counsel Officer
Transaction date
Planned sale
Price
2.12
Quantity 5,496 -22.1%
Value US$11,652
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.66
Quantity 17,094 -1.5%
Value US$62,624
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.58
Quantity 15,426 -1.3%
Value US$55,274
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.62
Quantity 3,446 -0.3%
Value US$12,478
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.82
Quantity 13,919 -1.2%
Value US$53,189
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.67
Quantity 6,025 -0.5%
Value US$22,111
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.30
Quantity 33,061 -2.7%
Value US$109,161
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.12
Quantity 20,535 -1.6%
Value US$63,981
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.25
Quantity 6,403 -0.5%
Value US$20,792
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.50
Quantity 8,064 -0.6%
Value US$28,251
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.49
Quantity 22,000 -1.7%
Value US$76,800
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.53
Quantity 14,331 -1.1%
Value US$50,597
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.71
Quantity 22,737 -1.7%
Value US$84,425
4.1
Szalay Aladar Large shareholder
Transaction date
Sale
Price
3.53
Quantity 48,683 -3.5%
Value US$171,802
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-04 2026-08-04 S Sale
3.2
Zindrick Thomas

President and CEO

Officer
21,986 -32.1%
171.38
US$2,355,077 		21,986 -32.1% 171.38 US$2,355,077
2026-08-04 2026-08-04 S Sale
3.8
Yu Yong

Chief Scientific Officer

Officer
48,236 -28.4%
177.61
US$2,180,848 		48,236 -28.4% 177.61 US$2,180,848
2026-08-04 2026-08-04 S Sale
3.4
Cappello Joseph

Chief Technical Officer

Officer
10,374 -34.0%
400.57
US$1,771,114 		10,374 -34.0% 400.57 US$1,771,114
2026-07-02 2026-07-01 S Sale
2.8
Smither John W
Non-Executive Director
12,000 -11.6%
2.91
US$34,898 		12,000 -11.6% 2.91 US$34,898
2026-07-01 2026-07-01 PrS Proposed sale
2.8
JOHN SMITHER

Director

Non-Executive Director
12,000
2.91
US$34,898 		12,000 2.91 US$34,898
2026-06-04 2026-06-03 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
192 -0.3%
2.93
US$563 		192 -0.3% 2.93 US$563
2026-06-02 2026-06-01 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.1%
2.98
US$29,801 		10,000 -2.1% 2.98 US$29,801
2026-06-01 2026-06-01 PrS Proposed sale
3.1
JOHNNY THOMAS

Officer

Officer
10,000
3.05
US$30,500 		10,000 3.05 US$30,500
2026-05-12 2026-05-11 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
270 -0.4%
2.98
US$804 		270 -0.4% 2.98 US$804
2026-05-12 2026-05-11 S Sale
3.2
Zindrick Thomas

President and CEO

Officer
2,798 -0.5%
2.94
US$8,226 		2,798 -0.5% 2.94 US$8,226
2026-05-12 2026-05-11 S Sale
3.4
Cappello Joseph

Chief Technical Officer

Officer
605 -0.4%
2.97
US$1,799 		605 -0.4% 2.97 US$1,799
2026-05-12 2026-05-11 S Sale
3.8
Yu Yong

Chief Scientific Officer

Officer
605 -0.4%
2.97
US$1,798 		605 -0.4% 2.97 US$1,798
2026-03-26 2026-03-25 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
240 -0.4%
2.51
US$602 		240 -0.4% 2.51 US$602
2026-03-26 2026-03-24 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
906 -0.6%
2.42
US$2,193 		906 -0.6% 2.42 US$2,193
2026-03-26 2026-03-24 S Sale
3.4
Cappello Joseph

Chief Technical Officer

Officer
906 -0.6%
2.42
US$2,193 		906 -0.6% 2.42 US$2,193
2026-03-26 2026-03-24 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
345 -0.5%
2.42
US$835 		345 -0.5% 2.42 US$835
2026-03-26 2026-03-24 S Sale
3.2
Zindrick Thomas

President and CEO

Officer
3,582 -0.7%
2.42
US$8,668 		3,582 -0.7% 2.42 US$8,668
2026-03-03 2026-03-02 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.0%
2.90
US$28,957 		10,000 -2.0% 2.90 US$28,957
2026-03-02 2026-03-02 PrS Proposed sale
3.1
JOHNNY THOMAS

Officer

Officer
10,000
2.98
US$29,800 		10,000 2.98 US$29,800
2025-12-09 2025-12-05 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
165 -0.2%
4.69
US$774 		165 -0.2% 4.69 US$774
2025-12-02 2025-12-01 PlS Planned sale
3.1
Thomas John
Non-Executive Director
10,000 -2.0%
5.00
US$50,008 		10,000 -2.0% 5.00 US$50,008
2025-12-01 2025-12-01 PrS Proposed sale
3.1
JOHNNY THOMAS

Director

Non-Executive Director
10,000
5.56
US$55,600 		10,000 5.56 US$55,600
2025-12-11 2025-11-17 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
973 -0.7%
5.37
US$5,224 		973 -0.7% 5.37 US$5,224
2025-12-11 2025-11-17 PlS Planned sale
3.2
Zindrick Thomas

President and CEO

Officer
4,509 -0.8%
5.37
US$24,211 		4,509 -0.8% 5.37 US$24,211
2025-12-11 2025-11-17 S Sale
3.4
Cappello Joseph

Chief Technical Officer

Officer
973 -0.6%
5.37
US$5,224 		973 -0.6% 5.37 US$5,224
2025-12-09 2025-11-17 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
343 -0.5%
5.37
US$1,842 		343 -0.5% 5.37 US$1,842
2025-12-09 2025-09-03 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
580 -0.8%
3.36
US$1,948 		580 -0.8% 3.36 US$1,948
2025-12-11 2025-08-21 S Sale
3.8
Yu Yong

SVP, Clinical Development

Officer
3,219 -2.1%
3.36
US$10,807 		3,219 -2.1% 3.36 US$10,807
2025-12-11 2025-08-21 PlS Planned sale
3.2
Zindrick Thomas

President and CEO

Officer
12,673 -2.3%
3.33
US$42,159 		12,673 -2.3% 3.33 US$42,159
2025-12-11 2025-08-21 S Sale
3.4
Cappello Joseph

Chief Technical Officer

Officer
1,463 -0.9%
3.36
US$4,912 		1,463 -0.9% 3.36 US$4,912
2025-12-11 2025-08-21 S Sale
3.4
Cappello Joseph

Chief Technical Officer

Officer
1,270 -0.8%
3.33
US$4,225 		1,270 -0.8% 3.33 US$4,225
2025-12-09 2025-08-21 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
1,244 -1.8%
3.36
US$4,177 		1,244 -1.8% 3.36 US$4,177
2025-05-13 2025-05-12 S Sale
3.2
Zindrick Thomas

President and CEO

Executive Director
10,764 -5.3%
2.92
US$31,431 		10,764 -5.3% 2.92 US$31,431
2025-05-13 2025-05-12 S Sale
3.3
Smalling Ralph

Head of Regulatory

Officer
1,259 -3.5%
2.92
US$3,676 		1,259 -3.5% 2.92 US$3,676
2025-05-13 2025-05-12 S Sale
2.6
Ryder Sean

General Counsel

Officer
4,475 -8.6%
2.92
US$13,067 		4,475 -8.6% 2.92 US$13,067
2025-05-13 2025-05-12 S Sale
3.4
Cappello Joseph

VP, Pharmaceutical Development

Officer
4,737 -8.3%
2.92
US$13,832 		4,737 -8.3% 2.92 US$13,832
2025-05-13 2025-05-12 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
5,579 -10.5%
2.92
US$16,291 		5,579 -10.5% 2.92 US$16,291
2024-12-30 2024-12-30 PrS Proposed sale
3.3
JAMES L TYREE

Director

Non-Executive Director
3,460
2.46
US$8,512 		3,460 2.46 US$8,512
2024-12-30 2024-12-30 S Sale
3.3
Tyree James L
Non-Executive Director
3,460 -7.0%
2.46
US$8,512 		3,460 -7.0% 2.46 US$8,512
2024-12-18 2024-12-16 PlS Planned sale
Zak Lourie S.

Chief Financial Officer

Officer
2,103 -4.9%
2.34
US$4,921 		2,103 -4.9% 2.34 US$4,921
2024-12-18 2024-12-16 PlS Planned sale
3.3
Smalling Ralph

Head of Regulatory

Officer
2,510 -13.3%
2.34
US$5,873 		2,510 -13.3% 2.34 US$5,873
2024-12-18 2024-12-16 S Sale
3.4
Cappello Joseph

VP, Pharmaceutical Development

Officer
6,300 -30.1%
2.34
US$14,742 		6,300 -30.1% 2.34 US$14,742
2024-12-18 2024-12-16 PlS Planned sale
3.2
Zindrick Thomas

President and CEO

Executive Director
14,315 -27.7%
2.34
US$33,497 		14,315 -27.7% 2.34 US$33,497
2024-09-13 2024-09-13 S Sale
4.1
Szalay Aladar
Large shareholder
33,080 -5.2%
2.57
US$84,946 		33,080 -5.2% 2.57 US$84,946
2024-09-13 2024-09-12 S Sale
4.1
Szalay Aladar
Large shareholder
31,777 -4.8%
2.73
US$86,732 		31,777 -4.8% 2.73 US$86,732
2024-09-12 2024-09-11 PlS Planned sale
3.3
Tyree James L
Non-Executive Director
1,730 -3.5%
2.60
US$4,499 		1,730 -3.5% 2.60 US$4,499
2024-09-11 2024-09-11 PrS Proposed sale
3.3
JAMES L TYREE

Director

Non-Executive Director
1,730
2.51
US$4,342 		1,730 2.51 US$4,342
2024-09-11 2024-09-11 S Sale
4.1
Szalay Aladar
Large shareholder
31,376 -4.5%
2.62
US$82,227 		31,376 -4.5% 2.62 US$82,227
2024-09-11 2024-09-10 S Sale
4.1
Szalay Aladar
Large shareholder
20,384 -2.8%
2.51
US$51,182 		20,384 -2.8% 2.51 US$51,182
2024-09-11 2024-09-09 S Sale
4.1
Szalay Aladar
Large shareholder
23,383 -3.2%
2.70
US$63,200 		23,383 -3.2% 2.70 US$63,200
2024-09-06 2024-09-09 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
140,000
2.80
US$392,000 		140,000 2.80 US$392,000
2024-09-06 2024-09-03 S Sale
4.1
Szalay Aladar
Large shareholder
42,818 -5.5%
2.09
US$89,614 		42,818 -5.5% 2.09 US$89,614
2024-08-30 2024-08-30 S Sale
4.1
Szalay Aladar
Large shareholder
142,589 -15.4%
2.17
US$309,846 		142,589 -15.4% 2.17 US$309,846
2024-08-30 2024-08-29 S Sale
4.1
Szalay Aladar
Large shareholder
107,045 -10.4%
1.98
US$211,960 		107,045 -10.4% 1.98 US$211,960
2024-08-30 2024-08-28 S Sale
4.1
Szalay Aladar
Large shareholder
15,918 -1.5%
2.05
US$32,605 		15,918 -1.5% 2.05 US$32,605
2024-08-27 2024-08-27 S Sale
4.1
Szalay Aladar
Large shareholder
51,630 -4.7%
2.11
US$108,862 		51,630 -4.7% 2.11 US$108,862
2024-08-27 2024-08-23 S Sale
4.1
Szalay Aladar
Large shareholder
40,000 -3.5%
2.29
US$91,416 		40,000 -3.5% 2.29 US$91,416
2024-08-22 2024-08-23 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
400,000
2.18
US$872,000 		400,000 2.18 US$872,000
2024-07-08 2024-06-24 S Sale
3.8
Yu Yong

VP, Clinical Trial Operations

Officer
6,849 -38.7%
2.12
US$14,520 		6,849 -38.7% 2.12 US$14,520
2024-07-08 2024-06-24 S Sale
2.4
Jewett Caroline

Head of Quality

Officer
4,961 -23.5%
2.12
US$10,517 		4,961 -23.5% 2.12 US$10,517
2024-07-08 2024-06-24 PlS Planned sale
2.6
Ryder Sean

General Counsel

Officer
5,496 -22.1%
2.12
US$11,652 		5,496 -22.1% 2.12 US$11,652
2024-05-15 2024-05-15 S Sale
4.1
Szalay Aladar
Large shareholder
17,094 -1.5%
3.66
US$62,624 		17,094 -1.5% 3.66 US$62,624
2024-05-15 2024-05-14 S Sale
4.1
Szalay Aladar
Large shareholder
15,426 -1.3%
3.58
US$55,274 		15,426 -1.3% 3.58 US$55,274
2024-05-15 2024-05-13 S Sale
4.1
Szalay Aladar
Large shareholder
3,446 -0.3%
3.62
US$12,478 		3,446 -0.3% 3.62 US$12,478
2024-05-09 2024-05-08 S Sale
4.1
Szalay Aladar
Large shareholder
13,919 -1.2%
3.82
US$53,189 		13,919 -1.2% 3.82 US$53,189
2024-05-09 2024-05-07 S Sale
4.1
Szalay Aladar
Large shareholder
6,025 -0.5%
3.67
US$22,111 		6,025 -0.5% 3.67 US$22,111
2024-05-01 2024-05-01 S Sale
4.1
Szalay Aladar
Large shareholder
33,061 -2.7%
3.30
US$109,161 		33,061 -2.7% 3.30 US$109,161
2024-05-01 2024-04-30 S Sale
4.1
Szalay Aladar
Large shareholder
20,535 -1.6%
3.12
US$63,981 		20,535 -1.6% 3.12 US$63,981
2024-05-01 2024-04-29 S Sale
4.1
Szalay Aladar
Large shareholder
6,403 -0.5%
3.25
US$20,792 		6,403 -0.5% 3.25 US$20,792
2024-04-24 2024-04-24 S Sale
4.1
Szalay Aladar
Large shareholder
8,064 -0.6%
3.50
US$28,251 		8,064 -0.6% 3.50 US$28,251
2024-04-24 2024-04-23 S Sale
4.1
Szalay Aladar
Large shareholder
22,000 -1.7%
3.49
US$76,800 		22,000 -1.7% 3.49 US$76,800
2024-04-24 2024-04-22 S Sale
4.1
Szalay Aladar
Large shareholder
14,331 -1.1%
3.53
US$50,597 		14,331 -1.1% 3.53 US$50,597
2024-04-18 2024-04-17 S Sale
4.1
Szalay Aladar
Large shareholder
22,737 -1.7%
3.71
US$84,425 		22,737 -1.7% 3.71 US$84,425
2024-04-18 2024-04-16 S Sale
4.1
Szalay Aladar
Large shareholder
48,683 -3.5%
3.53
US$171,802 		48,683 -3.5% 3.53 US$171,802
2024-04-15 2024-04-15 PrS Proposed sale
SZALAY 2010 RETAINED ANNUITY TRUST

10% Stockholder

Large shareholder
494,744
4.25
US$2,102,662 		494,744 4.25 US$2,102,662
Explore more

More insider trading research around Genelux Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America